Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Status:
Completed
Trial end date:
1999-01-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Determine the dose of recombinant human insulin-like growth factor I that minimizes or
decreases the need for exogenous glucose support without causing hypoglycemia.